Patents by Inventor Ole Hvilsted Olsen

Ole Hvilsted Olsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20160120954
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 5, 2016
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • COAGULATION FACTOR VII POLYPEPTIDES
    Publication number: 20160120992
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: November 9, 2015
    Publication date: May 5, 2016
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen, Carsten Behrens, Paul L. DeAngelis, Friedrich Michael Haller
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 9321827
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 26, 2016
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20160002314
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • COAGULATION FACTOR VII POLYPEPTIDES
    Publication number: 20150307865
    Abstract: The present invention relates to modified coagulation Factor VII (Factor VII) polypeptides having coagulant activity as well as polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 29, 2015
    Inventors: Henning R. Stennicke, Ole Hvilsted Olsen, Henrik Oestergaard
  • Compounds suitable for treatment of haemophilia
    Patent number: 9125890
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: September 8, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Gert Bolt, Ditte Maria Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • COAGULATION FACTOR VII POLYPEPTIDES
    Publication number: 20150105321
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Compounds Suitable for Treatment of Haemophilia
    Publication number: 20150080309
    Abstract: The present invention relates to VWF compounds as well as compositions suitable for treatment of blood clotting diseases.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 19, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens J. Hansen
  • Pharmaceutical Composition Suitable for Treatment of Haemophilia
    Publication number: 20150045303
    Abstract: The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Gert Bolt, Ditte M. Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Peder L. Noerby, Jens J. Hansen
  • FVIIa-sTF complexes exhibiting exosite-mediated super activity
    Publication number: 20150044195
    Abstract: Disclosed are disulphide-linked complexes of a soluble Tissue Factor (sTF) variant of SEQ ID NO:3 comprising the mutation G109C and a Factor VIIa variant of SEQ ID NO. 1, comprising the mutation Q64C and a mutation at position M306 that gives rise to a zymogen-like conformation in the Factor VIIa polypeptide. Said complexes may be used for the treatment of a coagulopathy.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 12, 2015
    Applicant: NOVO NORDISK HEALTHCARE AG
    Inventors: Henrik Oestergaard, Anders Laerke Nielsen, Ole Hvilsted Olsen
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20140057848
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 27, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor
    Patent number: 8652471
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: February 18, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • COMPOUNDS SUITABLE FOR TREATMENT OF HAEMOPHILIA
    Publication number: 20140018297
    Abstract: The present invention relates to Von Willebrand (VWF) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a Factor VIII molecule and (ii) a VWF compound.
    Type: Application
    Filed: June 12, 2013
    Publication date: January 16, 2014
    Inventors: Gert Bolt, Ditte Marie Karpf, Frederik Rode, Jesper Haaning, Kirstine Roepstorff, Lars Thim, Maj Petersen, Marianne Kjalke, Ole Hvilsted Olsen, Jens Jacob Hansen, Christian Rischel
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20130251721
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20130251722
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 20, 2012
    Publication date: September 26, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
  • Stable growth hormone compounds resistant to proteolytic degradation
    Patent number: 8513192
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 20, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
  • STABILIZED FACTOR VIII VARIANTS
    Publication number: 20130183280
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized Factor VIII molecules conjugated with a half life extending moiety as well as use of such molecules.
    Type: Application
    Filed: July 6, 2011
    Publication date: July 18, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Marianne Kjalke, Ole Hvilsted Olsen, Lars Thim, Henning Ralf Stennicke
  • Antibodies against tissue factor pathway inhibitor
    Patent number: 8361469
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: January 29, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Sørensen
  • Antibodies Against Tissue Factor Pathway Inhibitor
    Publication number: 20110318356
    Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.
    Type: Application
    Filed: December 18, 2009
    Publication date: December 29, 2011
    Applicant: NOVO Nordisk A/S
    Inventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Sørensen
  • STABLE GROWTH HORMONE COMPOUNDS
    Publication number: 20110306548
    Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.
    Type: Application
    Filed: January 22, 2010
    Publication date: December 15, 2011
    Applicant: Novo Nordisk Health Care AG
    Inventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen